SAFETY STARTS WITH THE STOPPING RULES
The KRYSTEXXA sUA Stopping Rules were developed after a post hoc analysis of the pivotal clinical trials. Data showed a correlation between the preinfusion sUA level rising above 6 mg/dL and the occurrence of infusion reactions for patients already on KRYSTEXXA.3
Since 95% of infusion reactions occurred when sUA levels were >6 mg/dL, preinfusion sUA levels were determined to be a powerful predictive biomarker for those adverse events.
Use these guidelines to help avoid anaphylaxis and other infusion reactions and ensure maximum safety.Download Stopping Rules